Oncolytics Biotech (ONCY) Non-Current Deffered Revenue (2017 - 2025)

Oncolytics Biotech (ONCY) has 9 years of Non-Current Deffered Revenue data on file, last reported at $4.9 million in Q4 2025.

• On a quarterly basis, Non-Current Deffered Revenue rose 1.92% year-over-year to $4.9 million in Q4 2025; TTM through Dec 2025 was $4.9 million, a 1.92% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 4.98% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $4.9 million, roughly flat from $4.9 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ONCY reached as high as $5.5 million in Q2 2021 and fell as low as $4.7 million in Q1 2025.
• Historically, Non-Current Deffered Revenue has averaged $5.1 million across 5 years, with a median of $5.0 million in 2023.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 3.42% in 2021 and fell as far as 20.99% in 2021.
• Year by year, Non-Current Deffered Revenue stood at $5.3 million in 2021, then dropped by 7.14% to $5.0 million in 2022, then dropped by 0.29% to $4.9 million in 2023, then fell by 2.54% to $4.8 million in 2024, then advanced by 1.92% to $4.9 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $4.9 million in Q4 2025, $4.9 million in Q3 2025, and $4.9 million in Q2 2025.